AliveDx Suisse S.A. and Disera Tibbi Malzeme Lojistik. san. Tic. A.S have signed a distribution agreement, which will enable Disera to distribute the MosaiQ® and LumiQ™ solutions in Türkiye. The distribution agreement takes effect immediately.
This strategic partnership with an important partner in Türkiye reaffirms AliveDx’s commitment to expanding its geographical presence and creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis. It will enable both parties to introduce new quality services to the healthcare industry and enhance patient care in the country.
The MosaiQ solution is a groundbreaking IVD platform for autoimmune diseases, allergies, and beyond. Its multiplexed, fully automated planar microarray technology enables syndromic testing for complex conditions. Designed for high throughput with continuous random access, MosaiQ delivers fast, accurate results to meet the evolving demands of laboratory efficiency. When combined with the LumiQ solution, these platforms provide a seamlessly integrated, turnkey approach to screening and confirming autoantibodies across a wide range of diseases—simplifying workflows and enhancing efficiency.
“The Turkish healthcare market is a top priority for AliveDx, as it stands among the most successful, mature, and developed healthcare systems in the EMEA region. It exemplifies the success of the ‘PPP’ (Public-Private Partnership) model in delivering state-of-the-art diagnostic solutions to patients. AliveDx is proud to contribute by providing best-in-class, high-quality diagnostic solutions for autoimmune diseases and beyond,” said Khaled Hamed, Head of Global Emerging Markets at AliveDx.
Disera was founded in 1996 in Izmir, Türkiye. It is an international company specialized in the production and development of blood collection tubes, blood collection accessories, urine collection systems, PRP products and a range of other hospital products. It is also active in the laboratory diagnostics sector within its domestic market.
“We are honored to collaborate with AliveDx as part of our commitment to expanding our diagnostic business portfolio. Adding AliveDx solutions marks a significant step in our growth within the immunology diagnostics segment. We believe the MosaiQ and LumiQ solutions will empower us to bring the latest, best-in-class technologies to the Turkish healthcare sector, driving a positive impact on patient care,” said Kenan Deniz Büyükakman, Disera’s General Manager.
To learn more, please visit the Disera website.
